Welcome to our dedicated page for Provectus Biopha news (Ticker: PVCT), a resource for investors and traders seeking the latest updates and insights on Provectus Biopha stock.
Provectus Biopharmaceuticals, Inc. (PVCT) is a clinical-stage biotechnology company whose news flow centers on the development of immunotherapy medicines based on halogenated xanthenes, particularly its lead molecule rose bengal sodium. As an OTCQB-traded company, Provectus regularly issues updates on preclinical and clinical research, investor events, and corporate initiatives that shape the outlook for its investigational programs.
News about Provectus often highlights progress with PV-10, the company’s rose bengal sodium-based investigational cancer immunotherapy. Recent announcements have covered preclinical studies in head and neck squamous cell carcinoma, orthotopic bladder cancer models using oral and intravesical PV-10, and mechanistic work showing activation of the STING immune pathway and enhanced T-cell responses in vaccine settings. These items provide insight into how the company is exploring PV-10 across oncology and immunology applications.
Investors and researchers following PVCT can also expect updates on wound healing and dermatology research, such as non-clinical data on full-thickness cutaneous wounds, as well as ophthalmology developments through the VisiRose founded entity focused on rose bengal sodium-based eye therapies. Additional news items include announcements of annual stockholder meetings, investor webinars, and conference calls, which offer company updates and access to management presentations.
This PVCT news page aggregates these disclosures in one place, making it easier to review Provectus’s latest scientific publications, collaboration highlights, and corporate communications. For anyone tracking the evolution of its rose bengal sodium platform across oncology, dermatology, ophthalmology, infectious diseases, and tissue repair research, this feed provides an organized view of the company’s reported milestones and ongoing activities.
Provectus (OTCQB: PVCT) announced preclinical research on its investigational cancer immunotherapy, PV-10, presented at the AACR annual meeting in New Orleans. The research, led by Dr. Aru Narendran, demonstrates PV-10's cytotoxic effects on high-risk solid tumor cell lines, including breast and colorectal cancers. Key findings reveal PV-10’s ability to modulate apoptosis and autophagy pathways, and inhibit cancer cell migration. PV-10 has been administered in over 450 patients and is under investigation for both local and systemic treatment of various cancers.
Provectus (OTCQB: PVCT) announced the successful development of a second halogenated xanthene (HX) molecule, enhancing its existing pipeline that includes the clinical-stage rose bengal sodium (RBS). The newly synthesized HX, with a complex molecular name, expands Provectus' proprietary intellectual property portfolio. The company adheres to Quality-by-Design (QbD) principles and cGMP guidelines for its products. Vice Chair Dominic Rodrigues expressed optimism about the potential of this new small molecule in drug development, aiming for it to become a viable drug candidate.
Provectus (OTCQB: PVCT) presented data from an ongoing clinical trial of its investigational cancer immunotherapy PV-10 for treating metastatic neuroendocrine tumors (mNET) at the ENETS conference.
Involving 12 patients, the study showed a median progression-free survival (mPFS) of 9.4 months and a median overall survival (mOS) of 22.5 months. The safety profile was favorable, with mostly Grade 1 or 2 adverse events. Potential combination therapies could enhance patient outcomes. The findings support PV-10 as a monotherapy option for patients resistant to standard treatments.
Provectus (OTCQB: PVCT) announced the acceptance of two abstracts for presentation at the 20th Congress of the International Society of Ocular Oncology, scheduled for June 17-21, 2022, in Leiden, Netherlands. The first abstract is a phase 1 study on PV-10 for metastatic uveal melanoma (mUM) patients. The second highlights metabolic complete responses in mUM patients treated with PV-10. PV-10 is an investigational cancer immunotherapy administered intralesionally to induce immune responses against tumors, having been used in over 450 patients with various malignancies.
Provectus (OTCQB: PVCT) announced preclinical research on its cancer immunotherapy PV-10, which will be presented at the AACR annual meeting from April 8-13, 2022, in New Orleans. The accepted abstract focuses on PV-10's anticancer effects on adult solid tumors, revealing its impact on protein kinase signaling pathways involved in autophagy and cell migration. PV-10 has shown promise in inducing immune responses and is being studied for multiple uses in treating solid tumors. The research highlights the potential of PV-10 in combination therapies, particularly for checkpoint blockade-refractory diseases.
Provectus (OTCQB: PVCT) announced that data from its clinical trial of PV-10 for treating metastatic neuroendocrine tumors (mNET) will be presented at the European Neuroendocrine Tumor Society conference on March 10-11, 2022. The abstract, accepted for oral presentation, focuses on the Phase 1 study of intralesional PV-10, a novel cancer immunotherapy. PV-10 has shown promise in inducing T cell responses against tumors, with over 450 patients treated to date in various cancer types. The company is also exploring systemic administration for broader cancer treatment applications.
Provectus (OTCQB: PVCT) has announced research advancements on its investigational immunotherapy PV-10 as an immune adjuvant aimed at enhancing vaccine efficacy against cancer and viruses. Recently, the USPTO published Provectus' patent application for using halogenated xanthenes in vaccines. In vitro data revealed that PV-10 significantly boosted interferon gamma-producing CD8 cells for Hepatitis B virus peptides. The company emphasizes its commitment to developing affordable immunotherapy medicines supported by this novel research.
Provectus (OTCQB: PVCT) announced the publication of preclinical research on its pharmaceutical-grade rose bengal, demonstrating its effectiveness against Gram-positive bacteria, including drug-resistant strains. The study, led by Dr. Michio Kurosu from the University of Tennessee Health Science Center, highlights that Provectus' formulation kills bacteria rapidly, eradicates biofilms, and shows low resistance development. The results support the potential of rose bengal as an anti-infective drug for skin and soft tissue infections, advancing its clinical application.
Provectus has revealed promising results from a meta-analysis of its Phase 2 and 3 clinical trials involving PV-10 for treating Stage III cutaneous melanoma. The analysis included 184 patients, boasting a median overall survival of 44.9 months. PV-10 demonstrated a 56% complete response rate across 774 injected lesions. Data from the expanded access program showed a rapid treatment response with favorable safety profiles. This substantial data set spans 12 years and over 1,200 lesions, indicating the drug’s effectiveness against locoregional melanoma, positioning it favorably against standard therapies.
Provectus announced updated results from its Phase 1b clinical trial of the cancer immunotherapy PV-10, in combination with Keytruda, for advanced cutaneous melanoma refractory to immune checkpoint blockade.
Key findings include a median overall survival of 34.1 months and a median progression-free survival of 4.9 months. The study reported a 5% complete response, a 26% objective response rate, and a 53% disease control rate. Treatment was mainly well-tolerated, with primarily grade 1-2 injection site reactions.